Skip to main content
. 2007 Aug 8;45(10):3270–3276. doi: 10.1128/JCM.01272-07

TABLE 2.

PCR assay results from a combined cohort of 264 subjects analyzing the utility of each assay for the diagnosis of BV, with Amsel clinical criteria used to define BVa

Bacterium Sensitivity (%) (95% CI) Specificity (%) (95% CI) OR (95% CI)
BVAB1 43.2 (33.0-54.1) 96.7 (93.0-98.5) 22.45 (8.90-56.6)
BVAB2 86.4 (77.3-92.2) 92.9 (88.2-95.8) 83.2 (35.6-195)
BVAB3 42.0 (31.8-52.9) 96.7 (93.0-98.5) 21.3 (8.5-53.9)
G. vaginalis 96.3 (89.7-98.7) 29.5 (23.4-36.5) 10.9 (3.3-36.0)
Atopobium spp. 96.3 (89.7-98.7) 77.05 (70.4-82.6) 87.3 (26.2-291)
Eggerthella-like bacterium 91.4 (83.2-95.8) 86.3 (80.6-90.6) 66.8 (27.65-162)
Leptotrichia spp. 82.7 (73.1-89.4) 89.1 (83.7-92.8) 39.0 (18.6-81.7)
Megasphaera phylotype 1 95.1 (88.0-98.1) 88.5 (83.1-92.4) 148.5 (49.3-448)
Megasphaera phylotype 2 18.5 (11.6-28.3) 98.9 (96.1-99.7) 20.6 (4.6-92.4)
Either Megasphaera sp. 97.5 (91.4-99.3) 88.5 (83.1-92.4) 305 (69.7-1,332)
BVAB-TM7 33.3 (24.0-44.2) 97.8 (94.5-99.2) 22.4 (7.5-66.8)
M. curtisii 55.6 (44.7-65.9) 92.9 (88.2-95.8) 16.3 (8.0-33.4)
M. mulieris 22.2 (14.5-32.4) 100 (97.9-100) Infinity
Either Mobiluncus sp. 65.4 (54.6-74.9) 92.9 (88.2-95.8) 24.8 (12.0-51.2)
Peptoniphilus sp. type 1 83.8 (74.1-90.3) 70.0 (63.0-76.1) 12.0 (6.1-23.5)
Peptoniphilus lacrimalis 70.4 (59.7-79.2) 78.1 (71.6-83.5) 8.5 (4.7-15.4)
Either Peptoniphilus sp. 88.9 (80.2-94.0) 60.7 (53.4-67.4) 12.3 (5.8-26.2)
Prevotella G1 63.8 (52.8-73.4) 94.0 (89.6-96.6) 27.5 (12.9-58.9)
L. crispatus 16.1 (9.6-25.6) 10.4 (6.8-15.7) 0.022 (0.01-0.05)
L. iners 98.8 (93.3-99.8) 8.8 (5.5-13.7) 7.7 (1.0-58.8)
Either BVAB1 or BVAB2 87.7 (78.7-93.2) 92.9 (88.2-95.8) 92.8 (38.9-222)
Either BVAB1 or BVAB3 48.2 (37.6-58.9) 95.1 (90.9-97.4) 18.0 (8.1-39.9)
Either BVAB2 or BVAB3 87.7 (78.7-93.2) 92.9 (88.2-95.8) 92.8 (38.9-222)
Either BVAB1, -2, or -3 87.7 (78.7-93.2) 92.9 (88.2-95.8) 92.8 (38.9-222)
Either Megasphaera phylotype 1 or BVAB2 98.8 (93.3-99.8) 88.5 (83.1-92.4) 617 (81.6-4,670)
a

The analysis consisted of 81 subjects with BV and 183 subjects without BV.

HHS Vulnerability Disclosure